$CTKB
Cytek Biosciences, Inc.

2023 Q4 Form 10-Q Financial Statement

#000162828023038974 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022
Revenue $58.23M $48.00M $164.0M
YoY Change 20.48% 18.59% 28.2%
Cost Of Revenue $25.19M $20.82M $63.06M
YoY Change 32.82% 52.93% 29.21%
Gross Profit $33.05M $27.18M $101.0M
YoY Change 12.51% 1.18% 27.58%
Gross Profit Margin 56.75% 56.62% 61.56%
Selling, General & Admin $22.32M $22.43M $67.92M
YoY Change 14.19% 33.08% 49.13%
% of Gross Profit 67.53% 82.52% 67.26%
Research & Development $10.87M $11.17M $34.86M
YoY Change 11.51% 29.14% 42.62%
% of Gross Profit 32.89% 41.1% 34.52%
Depreciation & Amortization $1.631M $900.0K $2.492M
YoY Change 114.32% 102.7% 100.64%
% of Gross Profit 4.94% 3.31% 2.47%
Operating Expenses $33.19M $33.60M $102.8M
YoY Change 13.3% 31.75% 46.85%
Operating Profit -$137.0K -$6.420M -$1.804M
YoY Change -263.1% -572.06% -119.7%
Interest Expense $1.054M $595.0K $2.573M
YoY Change -45.64% -8.32% 47.79%
% of Operating Profit
Other Income/Expense, Net $3.194M $2.235M $3.064M
YoY Change 52.75% 356.12% -195.18%
Pretax Income $4.111M -$4.185M $1.260M
YoY Change -0.07% -326.22% -78.78%
Income Tax -$1.392M $2.271M -$1.224M
% Of Pretax Income -33.86% -97.14%
Net Earnings $5.503M -$6.456M $2.484M
YoY Change 55.94% -497.05% -17.94%
Net Earnings / Revenue 9.45% -13.45% 1.51%
Basic Earnings Per Share $0.02
Diluted Earnings Per Share $0.04 -$0.05 $0.02
COMMON SHARES
Basic Shares Outstanding 135.5M shares 136.4M 134.5M
Diluted Shares Outstanding 136.2M shares 138.6M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $262.4M $288.0M $341.1M
YoY Change -23.08% -15.67% -6.44%
Cash & Equivalents $167.3M $163.6M $173.2M
Short-Term Investments $95.11M $124.4M $44.55M
Other Short-Term Assets $2.230M $2.250M $13.84M
YoY Change -41.25% 25.35% 160.63%
Inventory $60.88M $66.88M $48.15M
Prepaid Expenses
Receivables $55.93M $55.40M $48.86M
Other Receivables $192.0K $2.200M $2.011M
Total Short-Term Assets $392.1M $422.3M $454.0M
YoY Change -13.65% -4.85% 5.16%
LONG-TERM ASSETS
Property, Plant & Equipment $18.41M $17.42M $27.57M
YoY Change 34.52% 122.02% 371.12%
Goodwill $16.18M $16.46M
YoY Change 59.53% 62.23%
Intangibles $23.08M $24.29M
YoY Change 432.99% 441.63%
Long-Term Investments $1.600M $1.600M
YoY Change 0.0% 0.0%
Other Assets $3.385M $3.168M $23.42M
YoY Change 14.47% -30.51% 116.05%
Total Long-Term Assets $102.4M $97.12M $65.46M
YoY Change 56.44% 75.18% 107.32%
TOTAL ASSETS
Total Short-Term Assets $392.1M $422.3M $454.0M
Total Long-Term Assets $102.4M $97.12M $65.46M
Total Assets $494.5M $519.4M $519.5M
YoY Change -4.82% 4.03% 12.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.032M $4.700M $4.805M
YoY Change -36.9% -16.67% 58.37%
Accrued Expenses $20.04M $20.51M $25.48M
YoY Change -5.16% 23.3% 52.98%
Deferred Revenue $37.83M $38.01M
YoY Change 44.88% 68.91%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $565.0K $500.0K $580.0K
YoY Change -2.59%
Total Short-Term Liabilities $56.23M $58.69M $49.04M
YoY Change 14.65% 41.45% 47.8%
LONG-TERM LIABILITIES
Long-Term Debt $1.648M $1.700M $2.271M
YoY Change -27.43%
Other Long-Term Liabilities $2.431M $2.285M $42.62M
YoY Change 53.18% 59.01% 72.27%
Total Long-Term Liabilities $2.431M $2.285M $44.89M
YoY Change 53.18% 59.01% 81.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $56.23M $58.69M $49.04M
Total Long-Term Liabilities $2.431M $2.285M $44.89M
Total Liabilities $101.4M $103.9M $94.18M
YoY Change 7.95% 25.51% 61.65%
SHAREHOLDERS EQUITY
Retained Earnings -$29.18M -$34.68M
YoY Change 71.33% 68.69%
Common Stock $131.0K $136.0K
YoY Change -2.96% 0.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $393.1M $415.5M $425.3M
YoY Change
Total Liabilities & Shareholders Equity $494.5M $519.4M $519.5M
YoY Change -4.82% 4.03% 12.12%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022
OPERATING ACTIVITIES
Net Income $5.503M -$6.456M $2.484M
YoY Change 55.94% -497.05% -17.94%
Depreciation, Depletion And Amortization $1.631M $900.0K $2.492M
YoY Change 114.32% 102.7% 100.64%
Cash From Operating Activities $9.512M -$4.240M -$12.23M
YoY Change 53.59% -43.5% -364.17%
INVESTING ACTIVITIES
Capital Expenditures $1.561M $1.400M $9.748M
YoY Change -76.38% -221.74% 123.37%
Acquisitions
YoY Change
Other Investing Activities $30.63M $44.52M -$46.04M
YoY Change -168.9% 176.87%
Cash From Investing Activities $29.07M $43.12M -$55.91M
YoY Change -156.92% -3849.57% 166.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -33.75M -8.280M 5.513M
YoY Change -976.73% -5441.94% -97.42%
NET CHANGE
Cash From Operating Activities 9.512M -4.240M -12.23M
Cash From Investing Activities 29.07M 43.12M -55.91M
Cash From Financing Activities -33.75M -8.280M 5.513M
Net Change In Cash 4.824M 30.60M -65.12M
YoY Change -111.76% -460.04% -132.81%
FREE CASH FLOW
Cash From Operating Activities $9.512M -$4.240M -$12.23M
Capital Expenditures $1.561M $1.400M $9.748M
Free Cash Flow $7.951M -$5.640M -$21.98M
YoY Change -2006.71% -11.24% -8362.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q3 ctkb Noncontrolling Interest In Consolidated Subsidiary
NoncontrollingInterestInConsolidatedSubsidiary
0 usd
CY2022Q4 ctkb Noncontrolling Interest In Consolidated Subsidiary
NoncontrollingInterestInConsolidatedSubsidiary
251000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
415524000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
425546000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
519430000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
519476000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
134782000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
115700000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
58404000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
44100000 usd
us-gaap Gross Profit
GrossProfit
76378000 usd
us-gaap Gross Profit
GrossProfit
71600000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33282000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25111000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
37587000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
24201000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33217000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24176000 usd
us-gaap Operating Expenses
OperatingExpenses
104086000 usd
us-gaap Operating Expenses
OperatingExpenses
73488000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-27708000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1888000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
595000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
649000 usd
us-gaap Interest Expense
InterestExpense
1677000 usd
us-gaap Interest Expense
InterestExpense
1886000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
4965000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1993000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4600000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1073000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7888000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-966000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19820000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2854000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2169000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1620000 usd
us-gaap Profit Loss
ProfitLoss
-17651000 usd
us-gaap Profit Loss
ProfitLoss
-1234000 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 usd
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-40000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-281000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
1666000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1666000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17651000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17651000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-953000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-953000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.05
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.01
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.13
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.01
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.13
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.01
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
135862905 shares
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18533000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2661000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
204000 usd
CY2023Q1 ctkb Common Stock Withheld Related To Netshare Settlement
CommonStockWithheldRelatedToNetshareSettlement
57000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4699000 usd
CY2023Q1 ctkb Accumulated Marketable Securities Unrealized Gain Loss
AccumulatedMarketableSecuritiesUnrealizedGainLoss
152000 usd
CY2023Q1 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
-42000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6807000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-235000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
423460000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
483000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
966000 usd
CY2023Q2 ctkb Common Stock Withheld Related To Netshare Settlement
CommonStockWithheldRelatedToNetshareSettlement
111000 usd
CY2023Q2 ctkb Shares Buy Back Value
SharesBuyBackValue
981000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5922000 usd
CY2023Q2 ctkb Accumulated Marketable Securities Unrealized Gain Loss
AccumulatedMarketableSecuritiesUnrealizedGainLoss
-192000 usd
CY2023Q2 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
-980000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4388000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
424179000 usd
CY2023Q3 ctkb Shares Buy Back Value
SharesBuyBackValue
8428000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5758000 usd
CY2023Q3 ctkb Accumulated Marketable Securities Unrealized Gain Loss
AccumulatedMarketableSecuritiesUnrealizedGainLoss
15000 usd
CY2023Q3 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
165000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6456000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
405385000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
364000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3837000 usd
CY2022Q1 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
14000 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2021000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
137000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
407442000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1205000 usd
CY2022Q2 ctkb Common Stock Withheld Related To Netshare Settlement
CommonStockWithheldRelatedToNetshareSettlement
-67000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3934000 usd
CY2022Q2 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
-683000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-598000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-104000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
411129000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
224000 usd
CY2022Q3 ctkb Common Stock Withheld Related To Netshare Settlement
CommonStockWithheldRelatedToNetshareSettlement
71000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4359000 usd
CY2022Q3 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
-758000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1666000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
40000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
416509000 usd
us-gaap Profit Loss
ProfitLoss
-17651000 usd
us-gaap Profit Loss
ProfitLoss
-1234000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4417000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1731000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2388000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2064000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
16379000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
12130000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-7000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
ctkb Accounts Receivable Allowance For Credit Losses Period Increase Decrease
AccountsReceivableAllowanceForCreditLossesPeriodIncreaseDecrease
55000 usd
ctkb Accounts Receivable Allowance For Credit Losses Period Increase Decrease
AccountsReceivableAllowanceForCreditLossesPeriodIncreaseDecrease
0 usd
us-gaap Inventory Write Down
InventoryWriteDown
798000 usd
us-gaap Inventory Write Down
InventoryWriteDown
462000 usd
ctkb Loss Gain On Investments Accretion And Amortization Net
LossGainOnInvestmentsAccretionAndAmortizationNet
-5265000 usd
ctkb Loss Gain On Investments Accretion And Amortization Net
LossGainOnInvestmentsAccretionAndAmortizationNet
0 usd
ctkb Interest Expenses For Accretion Of Legal Settlement Liabilities
InterestExpensesForAccretionOfLegalSettlementLiabilities
1311000 usd
ctkb Interest Expenses For Accretion Of Legal Settlement Liabilities
InterestExpensesForAccretionOfLegalSettlementLiabilities
1611000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7595000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11780000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2047000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
19537000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2336000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15035000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
10000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2770000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
610000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2828000 usd
ctkb Increase Decrease In Legal Settlement Liabilities
IncreaseDecreaseInLegalSettlementLiabilities
-374000 usd
ctkb Increase Decrease In Legal Settlement Liabilities
IncreaseDecreaseInLegalSettlementLiabilities
478000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2154000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1408000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
7216000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
6496000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4231000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18424000 usd
ctkb Purchases Of Marketable Securities
PurchasesOfMarketableSecurities
-152563000 usd
ctkb Purchases Of Marketable Securities
PurchasesOfMarketableSecurities
0 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
78000000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3148000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3218000 usd
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
44896000 usd
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
118000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
40000 usd
us-gaap Payments To Acquire Real Estate Held For Investment
PaymentsToAcquireRealEstateHeldForInvestment
0 usd
us-gaap Payments To Acquire Real Estate Held For Investment
PaymentsToAcquireRealEstateHeldForInvestment
1587000 usd
ctkb Payment For Additional Investment In Cytek Japan Net Of Cash Acquired
PaymentForAdditionalInvestmentInCytekJapanNetOfCashAcquired
235000 usd
ctkb Payment For Additional Investment In Cytek Japan Net Of Cash Acquired
PaymentForAdditionalInvestmentInCytekJapanNetOfCashAcquired
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-122960000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4845000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
425000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
0 usd
ctkb Proceeds From Employee Stock Purchase Plans
ProceedsFromEmployeeStockPurchasePlans
966000 usd
ctkb Proceeds From Employee Stock Purchase Plans
ProceedsFromEmployeeStockPurchasePlans
765000 usd
ctkb Payments For Taxes Related To Net Share Settlement Of Equity Awards
PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards
317000 usd
ctkb Payments For Taxes Related To Net Share Settlement Of Equity Awards
PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards
138000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1127000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1036000 usd
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
9409000 usd
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8058000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1663000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-622000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1489000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-135871000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-23095000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
163629000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
341523000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
9930000 usd
us-gaap Nature Of Operations
NatureOfOperations
Description of business <div style="margin-top:6pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cytek Biosciences, Inc. (“Cytek” or the “Company”) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. The Company has focused on becoming the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical applications. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has successfully developed and manufactured its full spectrum flow cytometry platform (“instrument(s)” or “product(s)”). The Company believes its core instruments, the Aurora and Northern Lights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells (“Full Spectrum Profiling</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” or “FSP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). The Company’s FSP platform includes instruments, accessories, reagents, software, and services to provide a comprehensive and integrated suite of solutions for its customers. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2023, the Company completed the acquisition of the flow cytometry and imaging (“FCI”) business unit of Luminex Corporation ("Luminex"), including relating to the business of manufacturing, marketing, selling, servicing and maintaining Amnis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Guava</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> instruments, and flow cytometry reagent products and services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in the state of Delaware in December 2014 and is headquartered in Fremont, California with offices, manufacturing facilities and distribution channels across the globe.</span></div>
us-gaap Use Of Estimates
UseOfEstimates
Use of estimates The preparation of the unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s unaudited interim consolidated financial statements and accompanying notes as of the date of the unaudited interim consolidated financial statements. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
163600000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
299500000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
2900000 usd
CY2023Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2023Q3 us-gaap Cash
Cash
14725000 usd
CY2022Q4 us-gaap Cash
Cash
123371000 usd
CY2023Q3 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
23838000 usd
CY2022Q4 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
29930000 usd
CY2023Q3 us-gaap Us Government Agencies Securities At Carrying Value
USGovernmentAgenciesSecuritiesAtCarryingValue
0 usd
CY2022Q4 us-gaap Us Government Agencies Securities At Carrying Value
USGovernmentAgenciesSecuritiesAtCarryingValue
19908000 usd
CY2023Q3 us-gaap Commercial Paper At Carrying Value
CommercialPaperAtCarryingValue
0 usd
CY2022Q4 us-gaap Commercial Paper At Carrying Value
CommercialPaperAtCarryingValue
5955000 usd
CY2023Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
125066000 usd
CY2022Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
117437000 usd
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
0 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
2899000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
163629000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
299500000 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
102000 usd
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
55000 usd
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
157000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
48000000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
40477000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
134782000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
115700000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
48000000 usd
ctkb Upfront And Payment Terms
UpfrontAndPaymentTerms
P30D
CY2023Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
500000 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
2700000 usd
CY2022Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
500000 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
1600000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
40477000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
134782000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
115700000 usd
CY2023Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
38005000 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
55402000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
48864000 usd
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
38005000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
26110000 usd
CY2023Q3 ctkb Customer Deposit Liability Current
CustomerDepositLiabilityCurrent
1645000 usd
CY2022Q4 ctkb Customer Deposit Liability Current
CustomerDepositLiabilityCurrent
1555000 usd
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
39650000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
27665000 usd
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
17889000 usd
CY2022 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-24686000 usd
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
34462000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
27665000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-28657000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
40642000 usd
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
39650000 usd
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
37265000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
26925000 usd
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
11932000 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
4897000 usd
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
17678000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
16332000 usd
CY2023Q3 us-gaap Inventory Gross
InventoryGross
66875000 usd
CY2022Q4 us-gaap Inventory Gross
InventoryGross
48154000 usd
CY2023Q3 ctkb Prepaid Inventory
PrepaidInventory
559000 usd
CY2022Q4 ctkb Prepaid Inventory
PrepaidInventory
621000 usd
CY2023Q3 us-gaap Prepaid Rent
PrepaidRent
423000 usd
CY2022Q4 us-gaap Prepaid Rent
PrepaidRent
293000 usd
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
1055000 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1466000 usd
CY2023Q3 us-gaap Prepaid Taxes
PrepaidTaxes
2578000 usd
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
2080000 usd
CY2023Q3 ctkb Prepaid Value Added Tax
PrepaidValueAddedTax
760000 usd
CY2022Q4 ctkb Prepaid Value Added Tax
PrepaidValueAddedTax
0 usd
CY2023Q3 ctkb Prepaid Trade Show
PrepaidTradeShow
201000 usd
CY2022Q4 ctkb Prepaid Trade Show
PrepaidTradeShow
0 usd
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1960000 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2687000 usd
CY2023Q3 ctkb Tax Refund Receivable And Payable
TaxRefundReceivableAndPayable
2231000 usd
CY2022Q4 ctkb Tax Refund Receivable And Payable
TaxRefundReceivableAndPayable
2011000 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2250000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3796000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12017000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12954000 usd
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
13690000 usd
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
13911000 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
775000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1276000 usd
CY2023Q3 ctkb Accrued Purchases
AccruedPurchases
2248000 usd
CY2022Q4 ctkb Accrued Purchases
AccruedPurchases
2457000 usd
CY2023Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
2782000 usd
CY2022Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
2126000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1019000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1356000 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
20514000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
21126000 usd
CY2023Q3 ctkb Cashandcashequivalentsamortizedcostbasis
Cashandcashequivalentsamortizedcostbasis
124404000 usd
CY2023Q3 ctkb Customer Deposit Liability Current
CustomerDepositLiabilityCurrent
1645000 usd
CY2022Q4 ctkb Customer Deposit Liability Current
CustomerDepositLiabilityCurrent
1555000 usd
CY2023Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0 usd
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
246000 usd
CY2023Q3 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
2213000 usd
CY2022Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
1421000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2879000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2931000 usd
CY2023Q3 us-gaap Long Term Construction Loan Current
LongTermConstructionLoanCurrent
548000 usd
CY2022Q4 us-gaap Long Term Construction Loan Current
LongTermConstructionLoanCurrent
580000 usd
CY2023Q3 ctkb Other Current Liabilities Other
OtherCurrentLiabilitiesOther
536000 usd
CY2022Q4 ctkb Other Current Liabilities Other
OtherCurrentLiabilitiesOther
1227000 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7821000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7960000 usd
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
273296000 usd
CY2023Q3 ctkb Cashandcashequivalentsamortizedcostbasis
Cashandcashequivalentsamortizedcostbasis
124404000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
15000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
27000 usd
CY2023Q3 us-gaap Financial Instruments Owned Derivatives And Other Contractual Agreements At Fair Value
FinancialInstrumentsOwnedDerivativesAndOtherContractualAgreementsAtFairValue
124392000 usd
CY2023Q3 us-gaap Financial Instruments Owned Derivatives And Other Contractual Agreements At Fair Value
FinancialInstrumentsOwnedDerivativesAndOtherContractualAgreementsAtFairValue
124392000 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22468000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16841000 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5053000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3159000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17415000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13682000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
900000 usd
us-gaap Depreciation
Depreciation
2000000 usd
CY2022Q3 us-gaap Depreciation
Depreciation
400000 usd
us-gaap Depreciation
Depreciation
1200000 usd
CY2023Q1 ctkb Aggregate Cash Consideration
AggregateCashConsideration
44900000 usd
ctkb Upfront Payment
UpfrontPayment
2000000 usd
ctkb Royalty Payment Duration
RoyaltyPaymentDuration
P10Y
ctkb Mile Stone Payment
MileStonePayment
6000000 usd
CY2023Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P18M
CY2023Q3 ctkb Cost Of Sales Related To Royalty Expense
CostOfSalesRelatedToRoyaltyExpense
0 usd
ctkb Cost Of Sales Related To Royalty Expense
CostOfSalesRelatedToRoyaltyExpense
0 usd
CY2022Q3 ctkb Cost Of Sales Related To Royalty Expense
CostOfSalesRelatedToRoyaltyExpense
0 usd
ctkb Cost Of Sales Related To Royalty Expense
CostOfSalesRelatedToRoyaltyExpense
800000 usd
CY2023Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
48000000 usd
CY2022Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
49691000 usd
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
139359000 usd
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
145474000 usd
CY2023Q3 us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
-4185000 usd
CY2022Q3 us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
339000 usd
us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
-19180000 usd
us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
-7104000 usd
CY2023Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-6456000 usd
CY2022Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
475000 usd
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-17170000 usd
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-4471000 usd
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1500000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5710000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1379000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4331000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.91
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.64
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.14
CY2023Q3 us-gaap Litigation Settlement Interest
LitigationSettlementInterest
500000 usd
us-gaap Litigation Settlement Interest
LitigationSettlementInterest
1300000 usd
CY2022Q3 us-gaap Litigation Settlement Interest
LitigationSettlementInterest
600000 usd
us-gaap Litigation Settlement Interest
LitigationSettlementInterest
1600000 usd
CY2023Q3 ctkb Litigation Settlement Interest Payment Period Duration
LitigationSettlementInterestPaymentPeriodDuration
P10Y
CY2023Q3 ctkb Legal Settlement Liability Current
LegalSettlementLiabilityCurrent
2600000 usd
CY2022Q4 ctkb Legal Settlement Liability Current
LegalSettlementLiabilityCurrent
2163000 usd
CY2023Q3 ctkb Legal Settlement Liability Non Current
LegalSettlementLiabilityNonCurrent
16095000 usd
CY2022Q4 ctkb Legal Settlement Liability Non Current
LegalSettlementLiabilityNonCurrent
15596000 usd
CY2023Q3 ctkb Legal Settlement Liability
LegalSettlementLiability
18695000 usd
CY2022Q4 ctkb Legal Settlement Liability
LegalSettlementLiability
17759000 usd
CY2023Q3 ctkb Number Of Vote Per Share
NumberOfVotePerShare
1 vote
CY2021Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1.3333
CY2023Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.42
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.33
CY2023Q3 ctkb Number Of Stock Based Compensation Plan
NumberOfStockBasedCompensationPlan
3 plan
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7578635 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.76
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M1D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
37200000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1295948 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.09
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
911407 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.24
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
337754 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.08
ctkb Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
97257 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
15.22
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7528165 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.66
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M4D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
12753000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4533451 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.75
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M17D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11643000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5758000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4359000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16379000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12130000 usd
CY2023Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
469000 usd
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1238000 usd
CY2022Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
273000 usd
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
791000 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.110
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.568
us-gaap Operating Lease Cost
OperatingLeaseCost
2388000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
2370000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
639000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
37000 usd
us-gaap Lease Cost
LeaseCost
3027000 usd
us-gaap Lease Cost
LeaseCost
2407000 usd
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
68000000 usd
us-gaap Sublease Income
SubleaseIncome
204000000 usd
ctkb Operating Cash Outflows Payments On Operating Leases
OperatingCashOutflowsPaymentsOnOperatingLeases
2412000 usd
ctkb Operating Cash Outflows Payments On Operating Leases
OperatingCashOutflowsPaymentsOnOperatingLeases
1629000 usd
ctkb Right Of Use Assets Obtained In Exchange For New Lease Obligations
RightOfUseAssetsObtainedInExchangeForNewLeaseObligations
0 usd
ctkb Right Of Use Assets Obtained In Exchange For New Lease Obligations
RightOfUseAssetsObtainedInExchangeForNewLeaseObligations
16741000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11703000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13883000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2879000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2931000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10139000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12312000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
13018000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
15243000 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M21D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y5M19D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.026
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.026
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
843000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3063000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2665000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2571000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2315000 usd
CY2023Q3 ctkb Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
2395000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
13852000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
834000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
13018000 usd
CY2022Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
2126000 usd
CY2021Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1760000 usd
us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
2958000 usd
CY2022 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
2841000 usd
us-gaap Product Warranty Expense
ProductWarrantyExpense
2302000 usd
CY2022 us-gaap Product Warranty Expense
ProductWarrantyExpense
2475000 usd
CY2023Q3 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
2782000 usd
CY2022Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
2126000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-6456000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
1626000 usd
us-gaap Profit Loss
ProfitLoss
-17651000 usd
us-gaap Profit Loss
ProfitLoss
-1234000 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 usd
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-40000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-281000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6456000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6456000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
1666000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1666000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17651000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17651000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-953000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-953000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
136173278 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
134711701 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
135862905 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
134342059 shares
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3997634 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
136173278 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138709335 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
135862905 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
134342059 shares
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.05
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.01
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.13
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.01
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.05
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.01
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.13
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.01
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7200000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6200000 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3500000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4100000 shares
CY2023Q3 us-gaap Revenues
Revenues
48000000 usd
CY2022Q3 us-gaap Revenues
Revenues
40477000 usd
us-gaap Revenues
Revenues
134782000 usd
us-gaap Revenues
Revenues
115700000 usd
CY2023Q3 us-gaap Noncurrent Assets
NoncurrentAssets
17415000 usd
CY2022Q4 us-gaap Noncurrent Assets
NoncurrentAssets
13682000 usd

Files In Submission

Name View Source Status
0001628280-23-038974-index-headers.html Edgar Link pending
0001628280-23-038974-index.html Edgar Link pending
0001628280-23-038974.txt Edgar Link pending
0001628280-23-038974-xbrl.zip Edgar Link pending
ctkb-20230930.htm Edgar Link pending
ctkb-20230930.xsd Edgar Link pending
ctkb-20230930exx311.htm Edgar Link pending
ctkb-20230930exx312.htm Edgar Link pending
ctkb-20230930exx321.htm Edgar Link pending
ctkb-20230930exx322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
ctkb-20230930_def.xml Edgar Link unprocessable
ctkb-20230930_lab.xml Edgar Link unprocessable
ctkb-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ctkb-20230930_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
R93.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ctkb-20230930_cal.xml Edgar Link unprocessable